These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 9295237)

  • 1. On-line HPLC-tandem mass spectrometry analysis of contaminants of L-tryptophan associated with the onset of the eosinophilia-myalgia syndrome.
    Williamson BL; Benson LM; Tomlinson AJ; Mayeno AN; Gleich GJ; Naylor S
    Toxicol Lett; 1997 Jul; 92(2):139-48. PubMed ID: 9295237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. On-line HPLC-tandem mass spectrometry structural characterization of case-associated contaminants of L-tryptophan implicated with the onset of eosinophilia myalgia syndrome.
    Williamson BL; Johnson KL; Tomlinson AJ; Gleich GJ; Naylor S
    Toxicol Lett; 1998 Oct; 99(2):139-50. PubMed ID: 9817085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structural characterization of case-associated contaminants peak C and FF in L-tryptophan implicated in eosinophilia-myalgia syndrome.
    Naylor S; Williamson BL; Johnson KL; Gleich GJ
    Adv Exp Med Biol; 1999; 467():453-60. PubMed ID: 10721088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Peak AAA fatty acid homolog contaminants present in the dietary supplement l-Tryptophan associated with the onset of eosinophilia-myalgia syndrome.
    Klarskov K; Gagnon H; Racine M; Boudreault PL; Normandin C; Marsault E; Gleich GJ; Naylor S
    Toxicol Lett; 2018 Sep; 294():193-204. PubMed ID: 29800716
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure determination of disease associated peak AAA from l-Tryptophan implicated in the eosinophilia-myalgia syndrome.
    Klarskov K; Gagnon H; Boudreault PL; Normandin C; Plancq B; Marsault E; Gleich GJ; Naylor S
    Toxicol Lett; 2018 Jan; 282():71-80. PubMed ID: 29037509
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural characterization of contaminants found in commercial preparations of melatonin: similarities to case-related compounds from L-tryptophan associated with eosinophilia-myalgia syndrome.
    Williamson BL; Tomlinson AJ; Mishra PK; Gleich GJ; Naylor S
    Chem Res Toxicol; 1998 Mar; 11(3):234-40. PubMed ID: 9544622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Synthesis, formation, and occurrence of contaminants in biotechnologically manufactured L-tryptophan.
    Simat TJ; Kleeberg KK; Müller B; Sierts A
    Adv Exp Med Biol; 1999; 467():469-80. PubMed ID: 10721090
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Presence of peak X and related compounds: the reported contaminant in case related 5-hydroxy-L-tryptophan associated with eosinophilia-myalgia syndrome.
    Johnson KL; Klarskov K; Benson LM; Williamson BL; Gleich GJ; Naylor S
    J Rheumatol; 1999 Dec; 26(12):2714-7. PubMed ID: 10606395
    [No Abstract]   [Full Text] [Related]  

  • 9. 3-(Phenylamino)alanine, a novel aniline-derived amino acid associated with the eosinophilia-myalgia syndrome: a link to the toxic oil syndrome?
    Mayeno AN; Belongia EA; Lin F; Lundy SK; Gleich GJ
    Mayo Clin Proc; 1992 Dec; 67(12):1134-9. PubMed ID: 1469924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolism and distribution in the rat of peak E substance, a constituent in L-tryptophan product implicated in eosinophilia-myalgia syndrome.
    Adachi J; Naito T; Ueno Y; Ogawa Y; Ninomiya I; Tatsuno Y
    Arch Toxicol; 1993; 67(4):284-9. PubMed ID: 8517785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of contaminants in EMS-associated L-tryptophan samples by high-performance liquid chromatography.
    Toyo'oka T; Yamazaki T; Tanimoto T; Sato K; Sato M; Toyoda M; Ishibashi M; Yoshihira K; Uchiyama M
    Chem Pharm Bull (Tokyo); 1991 Mar; 39(3):820-2. PubMed ID: 2070471
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tryptophan contaminants associated with eosinophilia-myalgia syndrome. The Eosinophilia-Myalgia Studies of Oregon, New York and New Mexico.
    Philen RM; Hill RH; Flanders WD; Caudill SP; Needham L; Sewell L; Sampson EJ; Falk H; Kilbourne EM
    Am J Epidemiol; 1993 Aug; 138(3):154-9. PubMed ID: 8356958
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eosinophilia-myalgia syndrome case-associated contaminants in commercially available 5-hydroxytryptophan.
    Klarskov K; Johnson KL; Benson LM; Gleich GJ; Naylor S
    Adv Exp Med Biol; 1999; 467():461-8. PubMed ID: 10721089
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of four metabolites of 3-(phenylamino)alanine, a constituent in L-tryptophan products implicated in eosinophilia-myalgia syndrome, in rats.
    Adachi J; Mio T; Ueno Y; Naito T; Nishimura A; Fujiwara S; Sumino K; Tatsuno Y
    Arch Toxicol; 1994; 68(8):500-5. PubMed ID: 7802590
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rapid HPLC screening method for contaminants found in implicated L-tryptophan associated with eosinophilia myalgia syndrome and adulterated rapeseed oil associated with toxic oil syndrome.
    Williamson BL; Tomlinson AJ; Hurth KM; Posada de la Paz M; Gleich GJ; Naylor S
    Biomed Chromatogr; 1998; 12(5):255-61. PubMed ID: 9787895
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biotransformation of 3-(phenylamino)-1,2-propanediol to 3-(phenylamino)alanine: a chemical link between toxic oil syndrome and eosinophilia-myalgia syndrome.
    Mayeno AN; Benson LM; Naylor S; Colberg-Beers M; Puchalski JT; Gleich GJ
    Chem Res Toxicol; 1995; 8(7):911-6. PubMed ID: 8555405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contaminants in biotechnologically manufactured L-tryptophan.
    Simat T; van Wickern B; Eulitz K; Steinhart EH
    J Chromatogr B Biomed Appl; 1996 Oct; 685(1):41-51. PubMed ID: 8930752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The cause and pathogenesis of the eosinophilia-myalgia syndrome.
    Varga J; Uitto J; Jimenez SA
    Ann Intern Med; 1992 Jan; 116(2):140-7. PubMed ID: 1727618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced collagen synthesis and transcription by peak E, a contaminant of L-tryptophan preparations associated with the eosinophilia myalgia syndrome epidemic.
    Takagi H; Ochoa MS; Zhou L; Helfman T; Murata H; Falanga V
    J Clin Invest; 1995 Nov; 96(5):2120-5. PubMed ID: 7593596
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 1,1'-Ethylidenebis[L-tryptophan], an impurity in L-tryptophan associated with eosinophilia-myalgia syndrome, stimulates type I collagen gene expression in human fibroblasts in vitro.
    Zangrilli JG; Mayeno AN; Vining V; Varga J
    Biochem Mol Biol Int; 1995 Nov; 37(5):925-33. PubMed ID: 8624499
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.